Mirum Pharmaceuticals (NASDAQ:MIRM) Rating Reiterated by HC Wainwright

Posted by on Apr 8th, 2023

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $61.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 144.00% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. SVB Leerink decreased their price target on shares of Mirum Pharmaceuticals from $50.00 to $39.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 10th. Raymond James reduced their price objective on shares of Mirum Pharmaceuticals from $84.00 to $83.00 and set a “strong-buy” rating on the stock in a research note on Thursday, March 9th.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $25.00 on Thursday. The firm has a market capitalization of $948.75 million, a PE ratio of -6.22 and a beta of 1.32. The company’s 50-day moving average is $23.53 and its 200-day moving average is $21.42. Mirum Pharmaceuticals has a fifty-two week low of $17.32 and a fifty-two week high of $30.55.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors have recently made changes to their positions in MIRM. Charles Schwab Investment Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 5.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 15,500 shares of the company’s stock worth $342,000 after buying an additional 804 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Mirum Pharmaceuticals by 2.3% in the 4th quarter. Swiss National Bank now owns 48,100 shares of the company’s stock worth $938,000 after buying an additional 1,100 shares during the last quarter. Endurance Wealth Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 179.1% in the 4th quarter. Endurance Wealth Management Inc. now owns 1,954 shares of the company’s stock worth $38,000 after buying an additional 1,254 shares during the last quarter. Credit Suisse AG lifted its holdings in Mirum Pharmaceuticals by 16.1% during the third quarter. Credit Suisse AG now owns 12,175 shares of the company’s stock valued at $255,000 after purchasing an additional 1,692 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Mirum Pharmaceuticals by 29.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 9,500 shares of the company’s stock valued at $185,000 after purchasing an additional 2,150 shares during the last quarter.

About Mirum Pharmaceuticals

(Get Rating)

Mirum Pharmaceuticals, Inc is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Read More

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.